MIRNA CLERIE: Open Payments
NPI 1942447974 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$782 in 23 payments from 12 companies in 2025. Trend: 2023 $438 · 2024 $662 · 2025 $782
Food & beverage: $782
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $176 |
| Daiichi Sankyo Inc. | 2 | $157 |
| Novartis Pharmaceuticals Corporation | 5 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 1 | $39 |
| Janssen Biotech, Inc. | 1 | $35 |
| Invivyd Inc | 1 | $29 |
| Agios Pharmaceuticals, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $23 |
Products named: Enhertu, DATROWAY, KISQALI, PLUVICTO, KEYTRUDA, LIBTAYO, ERLEADA, FRUZAQLA.
Industry payments across DC — which companies pay providers there.
